During Wednesday’s trading session, shares of a pharmaceutical company involved in manufacturing and selling tablets, capsules, and other healthcare products jumped nearly 17.3 percent on NSE, after announcing H2 FY25 financial results with a rise in net profit by 72 percent HoH and 187 percent YoY.
With a market capitalisation of Rs. 89 crores, at 02:08 p.m., shares of Accretion Pharmaceuticals Limited were trading in the green at Rs. 79.9 on NSE, up by 14.5 percent, as against its previous closing price of Rs. 69.8.
What’s the News:
According to the latest regulatory filings on the NSE, Accretion Pharmaceuticals Limited announced the financial results for H2 FY25 on Tuesday after market hours.
For H2 FY25, Accretion Pharmaceuticals reported a revenue from operations of Rs. 38.8 crores, reflecting an impressive growth of around 109 percent HoH from Rs. 18.6 crores in H1 FY25, and a year-on-year rise of about 190 percent from Rs. 13.4 crores in H2 FY24.
Net profit for H2 FY25 stood at Rs. 4.3 crores, marking a nearly 72 percent HoH increase from Rs. 2.5 crores reported in H1 FY25, as well as an annual increase of around 187 percent from Rs. 1.5 crores in H2 FY24.
Earnings Before Interest, Taxes, Depreciation, and Amortisation (EBITDA) for H2 FY25 amounted to Rs. 7.5 crores, up by around 188 percent YoY from Rs. 2.6 crores in H2 FY24. EBITDA margin also expanded to 19.43 percent, compared to 19.25 percent, over the same period.
Incorporated in 2012, Accretion Pharmaceuticals Limited is engaged in the business of manufacturing and marketing of tablets, capsules, oral liquid, external preparations (ointment, cream, gel, lotion, medicated shampoo, mouthwash, dusting powder), and oral powder (sachet, dry syrup) etc. either for direct sales, loan licence and/or contract manufacturing.
Written by Shivani Singh
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
